6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
in O
greater O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Gastrointestinal B-OSE_Labeled_AE
Perforations I-OSE_Labeled_AE
and O
Fistulae O
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

* O
Surgery O
and O
Wound B-OSE_Labeled_AE
Healing I-OSE_Labeled_AE
Complications I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hemorrhage B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

* O
Arterial B-OSE_Labeled_AE
Thromboembolic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

* O
Venous B-OSE_Labeled_AE
Thromboembolic I-OSE_Labeled_AE
Events I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
. O

* O
Hypertension B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

* O
Posterior B-OSE_Labeled_AE
Reversible I-OSE_Labeled_AE
Encephalopathy I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

* O
Renal B-OSE_Labeled_AE
Injury I-OSE_Labeled_AE
and O
Proteinuria B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
. O

* O
Infusion B-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
. O

* O
Ovarian B-OSE_Labeled_AE
Failure I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
. O

* O
Congestive B-NonOSE_AE
Heart I-NonOSE_AE
Failure I-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
. O

] O
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
incidence O
( O
incidence O
> O
10 O
% O
) O
are O
epistaxis O
, O
headache O
, O
hypertension O
, O
rhinitis O
, O
proteinuria O
, O
taste O
alteration O
, O
dry O
skin O
, O
rectal O
hemorrhage O
, O
lacrimation O
disorder O
, O
back O
pain O
and O
exfoliative O
dermatitis O
. O

( O
6.1 O
) O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Genentech O
, O
Inc O
. O
at O
1-888-835-2555 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trial O
Experience O
Because O
clinical O
studies O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
studies O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
studies O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

The O
most O
common O
adverse O
reactions O
observed O
in O
patients O
receiving O
Avastin O
as O
a O
single O
agent O
or O
in O
combination O
with O
chemotherapy O
at O
a O
rate O
> O
10 O
% O
, O
are O
epistaxis B-OSE_Labeled_AE
, O
headache B-OSE_Labeled_AE
, O
hypertension B-OSE_Labeled_AE
, O
rhinitis B-OSE_Labeled_AE
, O
proteinuria B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
alteration I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
lacrimation B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
and O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
. O

The O
safety O
data O
below O
reflect O
exposure O
to O
Avastin O
in O
2919 O
patients O
with O
mCRC B-Not_AE_Candidate
, O
non-squamous O
NSCLC B-Not_AE_Candidate
, O
glioblastoma B-Not_AE_Candidate
, O
mRCC B-Not_AE_Candidate
, O
cervical B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
platinum-resistant O
or O
platinum-sensitive O
recurrent B-Not_AE_Candidate
epithelial I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
, O
fallopian O
tube O
, O
or O
primary O
peritoneal O
cancer I-Not_AE_Candidate
, O
including O
controlled O
studies O
( O
AVF2107g O
, O
E3200 O
, O
E4599 O
, O
EORTC O
26101 O
, O
BO17705 O
, O
GOG-0240 O
, O
MO22224 O
, O
AVF4095 O
, O
GOG-0213 O
) O
at O
the O
recommended O
dose O
and O
schedule O
for O
a O
median O
of O
6 O
to O
23 O
doses O
. O

Across O
clinical O
studies O
, O
Avastin O
was O
discontinued O
in O
8 O
% O
to O
22 O
% O
of O
patients O
because O
of O
adverse O
reactions O
[ O
see O
Clinical O
Studies O
( O
14 O
) O
] O
. O

Platinum O
- O
Resistant O
Recurrent O
Epithelia O
Ovarian O
, O
Fallopian O
Tube O
, O
or O
Primary O
Peritoneal O
Cancer O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
179 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
multicenter O
, O
open-label O
study O
( O
MO22224 O
) O
in O
which O
patients O
were O
randomized O
( O
1:1 O
) O
to O
Avastin O
with O
chemotherapy O
or O
chemotherapy O
alone O
in O
patients O
with O
platinum O
resistant O
, O
recurrent B-Not_AE_Candidate
epithelial I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
, O
fallopian O
tube O
, O
or O
primary O
peritoneal O
cancer I-Not_AE_Candidate
that O
recurred O
within O
< O
6 O
months O
from O
the O
most O
recent O
platinum O
based O
therapy O
. O

Patients O
were O
randomized O
to O
receive O
Avastin O
( O
10 O
mg/kg O
every O
2 O
weeks O
or O
15 O
mg/kg O
every O
3 O
weeks O
) O
. O

Patients O
had O
received O
no O
more O
than O
2 O
prior O
chemotherapy O
regimens O
. O

The O
trial O
excluded O
patients O
with O
evidence O
of O
recto B-Not_AE_Candidate
- I-Not_AE_Candidate
sigmoid I-Not_AE_Candidate
involvement I-Not_AE_Candidate
by O
pelvic O
examination O
or O
bowel B-Not_AE_Candidate
involvement I-Not_AE_Candidate
on O
CT O
scan O
or O
clinical O
symptoms O
of O
bowel B-Not_AE_Candidate
obstruction I-Not_AE_Candidate
. O

Patients O
were O
treated O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

Forty O
percent O
of O
patients O
on O
the O
chemotherapy O
alone O
arm O
received O
Avastin O
alone O
upon O
progression O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
2 O
. O

Table O
2 O
: O
Grade O
2-4 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
in O
Patients O
Receiving O
Avastin O
with O
Chemotherapy O
vs O
. O

Chemotherapy O
Alone O
in O
Study O
MO22224 O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Chemotherapy O
( O
N=179 O
) O
Chemotherapy O
( O
N=181 O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
31 O
% O
25 O
% O
General B-OSE_Labeled_AE
disorders I-OSE_Labeled_AE
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
13 O
% O
6 O
% O
Infections B-NonOSE_AE
Infection B-OSE_Labeled_AE
11 O
% O
4 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
18 O
% O
7 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
12 O
% O
0.6 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
5 O
% O
0 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysaesthesia I-OSE_Labeled_AE
11 O
% O
5 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
19 O
% O
6 O
% O
Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
179 O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
181 O
patients O
receiving O
chemotherapy O
alone O
were O
hypertension B-OSE_Labeled_AE
( O
6.7 O
% O
vs O
. O
1.1 O
% O
) O
and O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysaesthesia I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
4.5 O
% O
vs O
. O
1.7 O
% O
) O
. O

Platinum-Sensitive O
Recurrent O
Epithelial O
Ovarian O
, O
Fallopian O
Tube O
, O
or O
Primary O
Peritoneal O
Cancer O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
247 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
double-blind O
study O
( O
AVF4095g O
) O
in O
patients O
with O
platinum O
sensitive O
recurrent B-Not_AE_Candidate
epithelial I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
, O
fallopian O
tube O
or O
primary O
peritoneal O
cancer I-Not_AE_Candidate
. O

Patients O
were O
randomized O
( O
1:1 O
) O
to O
receive O
Avastin O
( O
15 O
mg/kg O
) O
or O
placebo O
every O
3 O
weeks O
with O
carboplatin O
and O
gemcitabine O
for O
6 O
to O
10 O
cycles O
followed O
by O
Avastin O
or O
placebo O
alone O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
3 O
. O

Table O
3 O
: O
Grade O
1-5 O
Adverse O
Reactions O
Occurring O
at O
a O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
in O
Patients O
Receiving O
Avastin O
with O
Chemotherapy O
vs O
. O

Placebo O
with O
Chemotherapy O
in O
Study O
AVF4095g O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Carboplatin O
and O
Gemcitabine O
( O
N=247 O
) O
Placebo O
with O
Carboplatin O
and O
Gemcitabine O
( O
N=233 O
) O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Thrombocytopenia B-OSE_Labeled_AE
58 O
% O
51 O
% O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
72 O
% O
66 O
% O
Diarrhea B-OSE_Labeled_AE
38 O
% O
29 O
% O
Stomatitis B-OSE_Labeled_AE
15 O
% O
7 O
% O
Hemorrhoids B-OSE_Labeled_AE
8 O
% O
3 O
% O
Gingival B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
7 O
% O
0 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
82 O
% O
75 O
% O
Mucosal B-OSE_Labeled_AE
inflammation I-OSE_Labeled_AE
15 O
% O
10 O
% O
Infections B-NonOSE_AE
Sinusitis B-OSE_Labeled_AE
15 O
% O
9 O
% O
Injury B-NonOSE_AE
and I-NonOSE_AE
procedural I-NonOSE_AE
complications I-NonOSE_AE
Contusion B-OSE_Labeled_AE
17 O
% O
9 O
% O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
28 O
% O
19 O
% O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
21 O
% O
13 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
49 O
% O
30 O
% O
Dizziness B-OSE_Labeled_AE
23 O
% O
17 O
% O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
21 O
% O
15 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
20 O
% O
3 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
55 O
% O
14 O
% O
Dyspnea B-OSE_Labeled_AE
30 O
% O
24 O
% O
Cough B-OSE_Labeled_AE
26 O
% O
18 O
% O
Oropharyngeal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
16 O
% O
10 O
% O
Dysphonia B-OSE_Labeled_AE
13 O
% O
3 O
% O
Rhinorrhea B-OSE_Labeled_AE
10 O
% O
4 O
% O
Sinus B-OSE_Labeled_AE
congestion I-OSE_Labeled_AE
8 O
% O
2 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
42 O
% O
9 O
% O
Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
placebo O
with O
chemotherapy O
were O
: O
thrombocytopenia B-OSE_Labeled_AE
( O
40 O
% O
vs O
. O
34 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1.3 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
4 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
0.9 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
0.4 O
% O
) O
, O
dyspnea B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1.7 O
% O
) O
, O
epistaxis B-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
0.4 O
% O
) O
, O
and O
hypertension B-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
0.9 O
% O
) O
. O

The O
safety O
of O
Avastin O
was O
evaluated O
in O
an O
open-label O
, O
controlled O
study O
, O
GOG-0213 O
, O
in O
325 O
patients O
with O
platinum-sensitive O
recurrent B-Not_AE_Candidate
epithelial I-Not_AE_Candidate
ovarian I-Not_AE_Candidate
, O
fallopian O
tube O
, O
or O
primary O
peritoneal O
cancer I-Not_AE_Candidate
, O
who O
have O
not O
received O
more O
than O
one O
previous O
regimen O
of O
chemotherapy O
. O

Patients O
were O
randomized O
( O
1:1 O
) O
to O
receive O
carboplatin O
and O
paclitaxel O
for O
6 O
to O
8 O
cycles O
or O
Avastin O
( O
15 O
mg/kg O
every O
3 O
weeks O
) O
with O
carboplatin O
and O
paclitaxel O
for O
6 O
to O
8 O
cycles O
followed O
by O
Avastin O
as O
a O
single O
agent O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
4 O
. O

Table O
4 O
: O
Grade O
1-5 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
in O
Patients O
Receiving O
Avastin O
with O
Chemotherapy O
vs O
. O

Chemotherapy O
Alone O
in O
Study O
GOG-0213 O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Carboplatin O
and O
Paclitaxel O
( O
N=325 O
) O
Carboplatin O
and O
Paclitaxel O
( O
N=332 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
39 O
% O
32 O
% O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
33 O
% O
28 O
% O
Vomiting B-OSE_Labeled_AE
33 O
% O
25 O
% O
Stomatitis B-OSE_Labeled_AE
33 O
% O
16 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
35 O
% O
25 O
% O
Hyperglycemia B-OSE_Labeled_AE
31 O
% O
24 O
% O
Hypomagnesemia B-OSE_Labeled_AE
27 O
% O
17 O
% O
Hyponatremia B-OSE_Labeled_AE
17 O
% O
6 O
% O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
15 O
% O
4 O
% O
Hypocalcemia B-OSE_Labeled_AE
12 O
% O
5 O
% O
Hypoalbuminemia B-OSE_Labeled_AE
11 O
% O
6 O
% O
Hyperkalemia B-OSE_Labeled_AE
9 O
% O
3 O
% O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Arthralgia B-OSE_Labeled_AE
45 O
% O
30 O
% O
Myalgia B-OSE_Labeled_AE
29 O
% O
18 O
% O
Pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
25 O
% O
14 O
% O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
17 O
% O
10 O
% O
Muscular B-OSE_Labeled_AE
weakness I-OSE_Labeled_AE
13 O
% O
8 O
% O
Neck B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
9 O
% O
0 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
33 O
% O
2 O
% O
Dyspnea B-OSE_Labeled_AE
30 O
% O
25 O
% O
Cough B-OSE_Labeled_AE
30 O
% O
17 O
% O
Rhinitis B-OSE_Labeled_AE
allergic I-OSE_Labeled_AE
17 O
% O
4 O
% O
Nasal B-OSE_Labeled_AE
mucosal I-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
14 O
% O
3 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
38 O
% O
20 O
% O
Dysarthria B-OSE_Labeled_AE
14 O
% O
2 O
% O
Dizziness B-OSE_Labeled_AE
13 O
% O
8 O
% O
Hepatic B-NonOSE_AE
Disorders I-NonOSE_AE
Aspartate B-OSE_Labeled_AE
aminotransferase I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
15 O
% O
9 O
% O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
23 O
% O
16 O
% O
Nail B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
10 O
% O
2 O
% O
Dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
7 O
% O
2 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
42 O
% O
3 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
17 O
% O
1 O
% O
Blood B-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
13 O
% O
5 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
8 O
% O
2 O
% O
Infections B-NonOSE_AE
Sinusitis B-OSE_Labeled_AE
7 O
% O
2 O
% O
Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
chemotherapy O
alone O
were O
: O
hypertension B-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
0.6 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
3 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
0 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
0.9 O
% O
) O
, O
hyponatremia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
0.9 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0.9 O
% O
) O
, O
and O
pain B-OSE_Labeled_AE
in I-OSE_Labeled_AE
extremity I-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0 O
% O
) O
. O

Metastatic O
Renal O
Cell O
Carcinoma O
( O
mRCC O
) O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
337 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
multicenter O
, O
double-blind O
study O
( O
BO17705 O
) O
in O
patients O
with O
metastatic B-Not_AE_Candidate
renal I-Not_AE_Candidate
cell I-Not_AE_Candidate
carcinoma I-Not_AE_Candidate
. O

Patients O
who O
had O
undergone O
a O
nephrectomy O
were O
randomized O
( O
1:1 O
) O
to O
receive O
either O
Avastin O
( O
10 O
mg/kg O
every O
2 O
weeks O
) O
or O
placebo O
with O
interferon O
alfa O
. O

Patients O
were O
treated O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Grade O
3-5 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
2 O
% O
) O
were O
fatigue B-OSE_Labeled_AE
( O
13 O
% O
vs O
. O
8 O
% O
) O
, O
asthenia B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
7 O
% O
) O
, O
proteinuria B-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
0 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
1 O
% O
; O
including O
hypertension B-OSE_Labeled_AE
and O
hypertensive B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
) O
, O
and O
hemorrhage B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0.3 O
% O
; O
including O
epistaxis B-OSE_Labeled_AE
, O
small O
intestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
aneurysm B-OSE_Labeled_AE
ruptured I-OSE_Labeled_AE
, O
gastric B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
gingival B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
hemoptysis B-OSE_Labeled_AE
, O
hemorrhage B-OSE_Labeled_AE
intracranial I-OSE_Labeled_AE
, O
large O
intestinal B-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
respiratory B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
hemorrhage I-OSE_Labeled_AE
, O
and O
traumatic B-OSE_Labeled_AE
hematoma I-OSE_Labeled_AE
) O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
5 O
. O

Table O
5 O
: O
Grades O
1-5 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
of O
Patients O
Receiving O
Avastin O
vs O
. O

Placebo O
with O
Interferon O
Alfa O
in O
Study O
BO17705 O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Interferon O
Alfa O
( O
N=337 O
) O
Placebo O
with O
Interferon O
Alfa O
( O
N=304 O
) O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
21 O
% O
16 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
33 O
% O
27 O
% O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
36 O
% O
31 O
% O
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
20 O
% O
15 O
% O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
connective I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Myalgia B-OSE_Labeled_AE
19 O
% O
14 O
% O
Back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
12 O
% O
6 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
24 O
% O
16 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Proteinuria B-OSE_Labeled_AE
20 O
% O
3 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
27 O
% O
4 O
% O
Dysphonia B-OSE_Labeled_AE
5 O
% O
0 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
28 O
% O
9 O
% O
The O
following O
adverse O
reactions O
were O
reported O
at O
a O
5-fold O
greater O
incidence O
in O
patients O
receiving O
Avastin O
with O
interferon-alfa O
compared O
to O
patients O
receiving O
placebo O
with O
interferon-alfa O
and O
not O
represented O
in O
Table O
3 O
: O
gingival B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
( O
13 O
patients O
vs O
. O
1 O
patient O
) O
; O
rhinitis B-OSE_Labeled_AE
( O
9 O
vs O
. O
0 O
) O
; O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
( O
8 O
vs O
. O
0 O
) O
; O
gingivitis B-OSE_Labeled_AE
( O
8 O
vs O
. O
1 O
) O
; O
gastroesophageal B-OSE_Labeled_AE
reflux I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( O
8 O
vs O
. O
1 O
) O
; O
tinnitus B-OSE_Labeled_AE
( O
7 O
vs O
. O
1 O
) O
; O
tooth B-OSE_Labeled_AE
abscess I-OSE_Labeled_AE
( O
7 O
vs O
. O
0 O
) O
; O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
( O
6 O
vs O
. O
0 O
) O
; O
acne B-OSE_Labeled_AE
( O
5 O
vs O
. O
0 O
) O
; O
deafness B-OSE_Labeled_AE
( O
5 O
vs O
. O
0 O
) O
; O
gastritis B-OSE_Labeled_AE
( O
5 O
vs O
. O
0 O
) O
; O
gingival B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
5 O
vs O
. O
0 O
) O
and O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
5 O
vs O
. O
1 O
) O
. O

Persistent O
, O
Recurrent O
, O
or O
Metastatic O
Cervical O
Cancer O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
218 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
multicenter O
study O
( O
GOG-0240 O
) O
in O
patients O
with O
persistent O
, O
recurrent B-Not_AE_Candidate
, O
or O
metastatic O
cervical I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

Patients O
were O
randomized O
( O
1:1:1:1 O
) O
to O
receive O
paclitaxel O
and O
cisplatin O
with O
or O
without O
Avastin O
( O
15 O
mg/kg O
every O
3 O
weeks O
) O
, O
or O
paclitaxel O
and O
topotecan O
with O
or O
without O
Avastin O
( O
15 O
mg/kg O
every O
3 O
weeks O
) O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
6 O
. O

Table O
6 O
: O
Grades O
1-4 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
5 O
% O
) O
in O
Patients O
Receiving O
Avastin O
with O
Chemotherapy O
vs O
. O

Chemotherapy O
Alone O
in O
Study O
GOG-0240 O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
Chemotherapy O
( O
N=218 O
) O
Chemotherapy O
( O
N=222 O
) O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
nutrition I-NonOSE_AE
disorders I-NonOSE_AE
Decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
34 O
% O
26 O
% O
Hyperglycemia B-OSE_Labeled_AE
26 O
% O
19 O
% O
Hypomagnesemia B-OSE_Labeled_AE
24 O
% O
15 O
% O
Weight B-OSE_Labeled_AE
Decreased I-OSE_Labeled_AE
21 O
% O
7 O
% O
Hyponatremia B-OSE_Labeled_AE
19 O
% O
10 O
% O
Hypoalbuminemia B-OSE_Labeled_AE
16 O
% O
11 O
% O
General B-NonOSE_AE
disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
80 O
% O
75 O
% O
Edema B-OSE_Labeled_AE
Peripheral I-OSE_Labeled_AE
15 O
% O
22 O
% O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
22 O
% O
14 O
% O
Infection B-OSE_Labeled_AE
10 O
% O
5 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
29 O
% O
6 O
% O
Thrombosis B-OSE_Labeled_AE
10 O
% O
3 O
% O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Headache B-OSE_Labeled_AE
22 O
% O
13 O
% O
Dysarthria B-OSE_Labeled_AE
8 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Stomatitis B-OSE_Labeled_AE
15 O
% O
10 O
% O
Proctalgia B-OSE_Labeled_AE
6 O
% O
1 O
% O
Anal B-OSE_Labeled_AE
fistula I-OSE_Labeled_AE
6 O
% O
0.0 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
12 O
% O
6 O
% O
Lymphopenia B-OSE_Labeled_AE
12 O
% O
5 O
% O
Psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
17 O
% O
10 O
% O
Reproductive B-NonOSE_AE
system I-NonOSE_AE
and I-NonOSE_AE
breast I-NonOSE_AE
disorders I-NonOSE_AE
Pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
14 O
% O
8 O
% O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Epistaxis B-OSE_Labeled_AE
17 O
% O
1 O
% O
Renal B-NonOSE_AE
and I-NonOSE_AE
urinary I-NonOSE_AE
disorders I-NonOSE_AE
Blood B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
16 O
% O
10 O
% O
Proteinuria B-OSE_Labeled_AE
10 O
% O
3 O
% O
Grade O
3-4 O
adverse O
reactions O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
218 O
patients O
receiving O
Avastin O
with O
chemotherapy O
compared O
to O
222 O
patients O
receiving O
chemotherapy O
alone O
were O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
12 O
% O
vs O
. O
10 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
0.5 O
% O
) O
, O
thrombosis B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
3 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
, O
anal B-OSE_Labeled_AE
fistula I-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
0 O
% O
) O
, O
proctalgia B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0 O
% O
) O
, O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
6 O
% O
) O
, O
cellulitis B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0.5 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
14 O
% O
vs O
. O
10 O
% O
) O
, O
hypokalemia B-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
4 O
% O
) O
, O
hyponatremia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1 O
% O
) O
, O
dehydration B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
0.5 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
4 O
% O
) O
, O
lymphopenia B-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
3 O
% O
) O
, O
and O
pelvic B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
6 O
% O
vs O
. O
1 O
% O
) O
. O

Metastatic O
Colorectal O
Cancer O
( O
mCRC O
) O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
392 O
patients O
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
a O
double-blind O
, O
active-controlled O
study O
( O
AVF2107g O
) O
, O
which O
compared O
Avastin O
( O
5 O
mg/kg O
every O
2 O
weeks O
) O
with O
bolus-IFL O
to O
placebo O
with O
bolus O
IFL O
in O
patients O
with O
mCRC O
. O

Patients O
were O
randomized O
( O
1:1:1 O
) O
to O
placebo O
with O
bolus O
IFL O
, O
Avastin O
with O
bolus O
IFL O
, O
or O
Avastin O
with O
5 O
fluorouracil O
and O
leucovorin O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

All O
Grade O
3-4 O
adverse O
reactions O
and O
selected O
Grade O
1-2 O
adverse O
reactions O
( O
i.e. O
, O
hypertension B-NonOSE_AE
, O
proteinuria B-NonOSE_AE
, O
thromboembolic B-NonOSE_AE
events I-NonOSE_AE
) O
were O
collected O
in O
the O
entire O
study O
population O
. O

Adverse O
reactions O
are O
presented O
in O
Table O
7 O
. O

Table O
7 O
: O
Grade O
3-4 O
Adverse O
Reactions O
Occurring O
at O
Higher O
Incidence O
( O
> O
= O
2 O
% O
) O
in O
Patients O
Receiving O
Avastin O
vs O
. O

Placebo O
in O
Study O
AVF2107g O
Adverse O
Reaction O
[ O
note O
: O
NCI-CTC O
version O
3 O
] O
Avastin O
with O
IFL O
( O
N=392 O
) O
Placebo O
with O
IFL O
( O
N=396 O
) O
General B-NonOSE_AE
disorders I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
10 O
% O
7 O
% O
Pain B-OSE_Labeled_AE
8 O
% O
5 O
% O
Vascular B-NonOSE_AE
disorders I-NonOSE_AE
Hypertension B-OSE_Labeled_AE
12 O
% O
2 O
% O
Deep B-OSE_Labeled_AE
Vein I-OSE_Labeled_AE
Thrombosis I-OSE_Labeled_AE
9 O
% O
5 O
% O
Intra B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Abdominal I-OSE_Labeled_AE
Thrombosis I-OSE_Labeled_AE
3 O
% O
1 O
% O
Syncope B-OSE_Labeled_AE
3 O
% O
1 O
% O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Diarrhea B-OSE_Labeled_AE
34 O
% O
25 O
% O
Abdominal B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
8 O
% O
5 O
% O
Constipation B-OSE_Labeled_AE
4 O
% O
2 O
% O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
disorders I-NonOSE_AE
Leukopenia B-OSE_Labeled_AE
37 O
% O
31 O
% O
Neutropenia B-OSE_Labeled_AE
21 O
% O
14 O
% O
The O
safety O
of O
Avastin O
was O
evaluated O
in O
521 O
patients O
in O
an O
open-label O
, O
active-controlled O
study O
( O
E3200 O
) O
. O

Patients O
who O
were O
previously O
treated O
with O
irinotecan O
and O
fluorouracil O
for O
initial O
therapy O
for O
metastatic B-Not_AE_Candidate
colorectal I-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

Patients O
were O
randomized O
( O
1:1:1 O
) O
to O
FOLFOX4 O
, O
Avastin O
( O
10 O
mg/kg O
every O
2 O
weeks O
prior O
to O
FOLFOX4 O
on O
Day O
1 O
) O
with O
FOLFOX4 O
, O
or O
Avastin O
alone O
( O
10 O
mg/kg O
every O
2 O
weeks O
) O
. O

Avastin O
was O
continued O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

The O
most O
frequent O
adverse O
reactions O
( O
selected O
Grade O
3-5 O
non-hematologic O
and O
Grade O
4-5 O
hematologic O
) O
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
patients O
receiving O
Avastin O
with O
FOLFOX4 O
compared O
to O
FOLFOX4 O
alone O
were O
fatigue B-OSE_Labeled_AE
( O
19 O
% O
vs O
. O
13 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
( O
18 O
% O
vs O
. O
13 O
% O
) O
, O
sensory B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
( O
17 O
% O
vs O
. O
9 O
% O
) O
, O
nausea B-OSE_Labeled_AE
( O
12 O
% O
vs O
. O
5 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
( O
11 O
% O
vs O
. O
4 O
% O
) O
, O
dehydration B-OSE_Labeled_AE
( O
10 O
% O
vs O
. O
5 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
9 O
% O
vs O
. O
2 O
% O
) O
, O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
5 O
% O
) O
, O
hemorrhage B-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
1 O
% O
) O
, O
other B-OSE_Labeled_AE
neurological I-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
3 O
% O
) O
, O
ileus B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1 O
% O
) O
and O
headache B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0 O
% O
) O
. O

These O
data O
are O
likely O
to O
under-estimate O
the O
true O
adverse O
event O
rates O
due O
to O
the O
reporting O
mechanisms O
. O

First-Line O
Non O
Squamous O
Non O
Small O
Cell O
Lung O
Cancer O
( O
NSCLC O
) O
The O
safety O
of O
Avastin O
was O
evaluated O
as O
first-line O
treatment O
in O
422 O
patients O
with O
unresectable O
NSCLC B-Not_AE_Candidate
who O
received O
at O
least O
one O
dose O
of O
Avastin O
in O
an O
active-controlled O
, O
open-label O
, O
multicenter O
trial O
( O
E4599 O
) O
. O

Chemotherapy O
naive O
patients O
with O
locally O
advanced O
, O
metastatic O
or O
recurrent O
non-squamous O
NSCLC B-Not_AE_Candidate
were O
randomized O
( O
1:1 O
) O
to O
receive O
six O
21 O
day O
cycles O
of O
paclitaxel O
and O
carboplatin O
with O
or O
without O
Avastin O
( O
15 O
mg/kg O
every O
3 O
weeks O
) O
. O

After O
completion O
or O
upon O
discontinuation O
of O
chemotherapy O
, O
patients O
randomized O
to O
receive O
Avastin O
continued O
to O
receive O
Avastin O
alone O
until O
disease O
progression O
or O
until O
unacceptable O
toxicity O
. O

The O
trial O
excluded O
patients O
with O
predominant O
squamous O
histology O
( O
mixed O
cell O
type O
tumors O
only O
) O
, O
CNS B-Not_AE_Candidate
metastasis I-Not_AE_Candidate
, O
gross B-Not_AE_Candidate
hemoptysis I-Not_AE_Candidate
( O
1/2 O
teaspoon O
or O
more O
of O
red O
blood O
) O
, O
unstable B-Not_AE_Candidate
angina I-Not_AE_Candidate
, O
or O
receiving O
therapeutic O
anticoagulation O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

Only O
Grade O
3-5 O
non O
hematologic O
and O
Grade O
4-5 O
hematologic B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
were O
collected O
. O

Grade O
3-5 O
non B-NonOSE_AE
hematologic I-NonOSE_AE
and O
Grade O
4-5 O
hematologic O
adverse I-NonOSE_AE
reactions I-NonOSE_AE
occurring O
at O
a O
higher O
incidence O
( O
> O
= O
2 O
% O
) O
in O
patients O
receiving O
Avastin O
with O
paclitaxel O
and O
carboplatin O
compared O
with O
patients O
receiving O
chemotherapy O
alone O
were O
neutropenia B-OSE_Labeled_AE
( O
27 O
% O
vs O
. O
17 O
% O
) O
, O
fatigue B-OSE_Labeled_AE
( O
16 O
% O
vs O
. O
13 O
% O
) O
, O
hypertension B-OSE_Labeled_AE
( O
8 O
% O
vs O
. O
0.7 O
% O
) O
, O
infection O
without O
neutropenia B-OSE_Labeled_AE
( O
7 O
% O
vs O
. O
3 O
% O
) O
, O
venous B-OSE_Labeled_AE
thromboembolism I-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
3 O
% O
) O
, O
febrile B-OSE_Labeled_AE
neutropenia I-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
2 O
% O
) O
, O
pneumonitis B-OSE_Labeled_AE
/ O
pulmonary B-OSE_Labeled_AE
infiltrates I-OSE_Labeled_AE
( O
5 O
% O
vs O
. O
3 O
% O
) O
, O
infection O
with O
Grade O
3 O
or O
4 O
neutropenia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
2 O
% O
) O
, O
hyponatremia B-OSE_Labeled_AE
( O
4 O
% O
vs O
. O
1 O
% O
) O
, O
headache B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
1 O
% O
) O
and O
proteinuria B-OSE_Labeled_AE
( O
3 O
% O
vs O
. O
0 O
% O
) O
. O

Recurrent O
Glioblastoma O
EORTC O
26101 O
was O
a O
multicenter O
, O
randomized O
, O
open-label O
study O
in O
patients O
with O
recurrent B-Not_AE_Candidate
GBM I-Not_AE_Candidate
following O
radiotherapy O
and O
temozolomide O
of O
whom O
278 O
patients O
received O
at O
least O
one O
dose O
of O
Avastin O
and O
are O
considered O
safety O
evaluable O
. O

Patients O
were O
randomized O
( O
2:1 O
) O
to O
receive O
Avastin O
( O
10 O
mg/kg O
every O
2 O
weeks O
) O
with O
lomustine O
or O
lomustine O
alone O
until O
disease O
progression O
or O
unacceptable O
toxicity O
. O

The O
demographics O
of O
the O
safety O
population O
were O
similar O
to O
the O
demographics O
of O
the O
efficacy O
population O
. O

In O
the O
Avastin O
with O
lomustine O
arm O
, O
22 O
% O
of O
patients O
discontinued O
treatment O
due O
to O
adverse O
reactions O
compared O
with O
10 O
% O
of O
patients O
in O
the O
lomustine O
arm O
. O

In O
patients O
receiving O
Avastin O
with O
lomustine O
, O
the O
adverse O
reaction O
profile O
was O
similar O
to O
that O
observed O
in O
other O
approved O
indications O
. O

6.2 O
Immunogenicity O
As O
with O
all O
therapeutic O
proteins O
, O
there O
is O
a O
potential O
for O
immunogenicity B-OSE_Labeled_AE
. O

The O
detection O
of O
antibody B-NonOSE_AE
formation I-NonOSE_AE
is O
highly O
dependent O
on O
the O
sensitivity O
and O
specificity O
of O
the O
assay O
. O

Additionally O
, O
the O
observed O
incidence O
of O
antibody B-NonOSE_AE
( O
including O
neutralizing O
antibody O
) O
positivity I-NonOSE_AE
in O
an O
assay O
may O
be O
influenced O
by O
several O
factors O
, O
including O
assay O
methodology O
, O
sample O
handling O
, O
timing O
of O
sample O
collection O
, O
concomitant O
medications O
, O
and O
underlying O
disease O
. O

For O
these O
reasons O
, O
comparison O
of O
the O
incidence O
of O
antibodies B-NonOSE_AE
to I-NonOSE_AE
bevacizumab I-NonOSE_AE
in O
the O
studies O
described O
below O
with O
the O
incidence O
of O
antibodies B-NonOSE_AE
in O
other O
studies O
or O
to I-NonOSE_AE
other I-NonOSE_AE
products I-NonOSE_AE
may O
be O
misleading O
. O

In O
clinical O
studies O
for O
adjuvant O
treatment O
of O
a O
solid O
tumor B-NonOSE_AE
, O
0.6 O
% O
( O
14/2323 O
) O
of O
patients O
tested O
positive O
for O
treatment-emergent O
anti B-OSE_Labeled_AE
- I-OSE_Labeled_AE
bevacizumab I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
as O
detected O
by O
an O
electrochemiluminescent O
( O
ECL O
) O
based O
assay O
. O

Among O
these O
14 O
patients O
, O
three O
tested O
positive B-OSE_Labeled_AE
for I-OSE_Labeled_AE
neutralizing I-OSE_Labeled_AE
antibodies I-OSE_Labeled_AE
against O
bevacizumab O
using O
an O
enzyme-linked O
immunosorbent O
assay O
( O
ELISA O
) O
. O

The O
clinical O
significance O
of O
these O
anti B-NonOSE_AE
- I-NonOSE_AE
bevacizumab I-NonOSE_AE
antibodies I-NonOSE_AE
is O
not O
known O
. O

6.3 O
Postmarketing O
Experience O
The O
following O
adverse O
reactions O
have O
been O
identified O
during O
post-approval O
use O
of O
Avastin O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
Polyserositis B-OSE_Labeled_AE
Cardiovascular B-NonOSE_AE
: O
Pulmonary B-OSE_Labeled_AE
hypertension I-OSE_Labeled_AE
, O
Mesenteric B-OSE_Labeled_AE
venous I-OSE_Labeled_AE
occlusion I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
: O
Gastrointestinal B-OSE_Labeled_AE
ulcer I-OSE_Labeled_AE
, O
Intestinal B-OSE_Labeled_AE
necrosis I-OSE_Labeled_AE
, O
Anastomotic B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
Hemic B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
: O
Pancytopenia B-OSE_Labeled_AE
Hepatobiliary B-NonOSE_AE
disorders I-NonOSE_AE
: O
Gallbladder B-OSE_Labeled_AE
perforation I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Osteonecrosis B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
jaw I-OSE_Labeled_AE
Renal O
: O
Renal B-OSE_Labeled_AE
thrombotic I-OSE_Labeled_AE
microangiopathy I-OSE_Labeled_AE
( O
manifested O
as O
severe O
proteinuria B-NonOSE_AE
) O
Respiratory B-NonOSE_AE
: O
Nasal B-OSE_Labeled_AE
septum I-OSE_Labeled_AE
perforation I-OSE_Labeled_AE

